180 Life Sciences Corp. has failed to meet the Nasdaq's minimum stockholders' equity requirement and faces potential delisting. The company was previously notified by Nasdaq on November 15, 2023, of its non-compliance with the $2.5 million equity threshold. Despite submitting a compliance plan and being granted an extension until May 13, 2024, 180 Life Sciences was unable to complete the necessary transactions to meet the requirement. Consequently, on May 14, 2024, Nasdaq issued a delisting determination letter to the company. 180 Life Sciences plans to request a hearing with the Nasdaq Hearings Panel in an attempt to present a new compliance plan and delay delisting. Trading of the company's common stock, under the symbol 'ATNF', will continue on Nasdaq pending the hearing's outcome. Additionally, on the...Show More

180 Life Sciences Corp. has failed to meet the Nasdaq's minimum stockholders' equity requirement and faces potential delisting. The company was previously notified by Nasdaq on November 15, 2023, of its non-compliance with the $2.5 million equity threshold. Despite submitting a compliance plan and being granted an extension until May 13, 2024, 180 Life Sciences was unable to complete the necessary transactions to meet the requirement. Consequently, on May 14, 2024, Nasdaq issued a delisting determination letter to the company. 180 Life Sciences plans to request a hearing with the Nasdaq Hearings Panel in an attempt to present a new compliance plan and delay delisting. Trading of the company's common stock, under the symbol 'ATNF', will continue on Nasdaq pending the hearing's outcome. Additionally, on the same day, the company was notified of non-compliance with Nasdaq's audit committee requirements, which mandates at least three independent directors. The company is seeking to address this issue and expects to regain compliance soon. The potential delisting could significantly impact the company's stock and warrant prices and its ability to raise capital.